Ravandi, F., Ritchie, E. K., Sayar, H., Lancet, J. E., Craig, M. D., Vey, N., Strickland, S. A., Schiller, G. J., Jabbour, E., Pigneux, A., Horst, H.-A., Récher, C., Klimek, V. M., Cortes, J. E., Carella, A.-M., Egyed, M., Krug, U., Fox, J. A., Craig, A. R., Ward, R., Smith, J. A., Acton, G., Kantarjian, H. M. and Stuart, R. K. (2018) “Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia”, Haematologica. Pavia, Italy, 103(11), pp. e514-e518. doi: 10.3324/haematol.2018.191361.